Drugs in Dev.
Infections and Infectious Diseases
Phase I
Ireland 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : EG-009A
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Evergreen Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : The purpose of the study is to evaluate the efficacy of Evergreen’s EG-009A drug candidate for the treatment of moderate to severe COVID-19 cases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 18, 2021
Lead Product(s) : EG-009A
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Evergreen Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SARS-CoV-2 Vaccine, Live Attenuated
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Codagenix
Deal Size : Inapplicable
Deal Type : Inapplicable
Open Orphan Receoves MHRA Approval for Nasal COVID-19 Vaccine Trial
Details : The study will assess the safety and immunogenicity of a single-dose nasal vaccine candidate COVI-VAC in 48 healthy young adult volunteers.
Product Name : Covi-vac
Product Type : Vaccine
Upfront Cash : Inapplicable
December 14, 2020
Lead Product(s) : SARS-CoV-2 Vaccine, Live Attenuated
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Codagenix
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Defibrotide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Gregory Yanik
Deal Size : Inapplicable
Deal Type : Inapplicable
Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)
Details : Defibrotide is a Oligonucleotide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
August 28, 2020
Lead Product(s) : Defibrotide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Gregory Yanik
Deal Size : Inapplicable
Deal Type : Inapplicable
